33
Views
3
CrossRef citations to date
0
Altmetric
Anticancer Chemotherapy

Intra-Arterial Chemotherapy with Gemcitabine and Cisplatin for Patients with Recurrence of Transitional Cell Carcinoma Confined to the Pelvis

Pages 91-97 | Published online: 18 Jul 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

M.K. Chen, Z.K. Qin, F.J. Zhou, H. Han, Z.W. Liu, Y.H. Li, K. Yao, G.L. Hou, Y.L. Ye, Z.L. Zhang, H. Tu, X.Q. Zhang, K.S. Lu & Z.W. Yang. (2009) Intra-Arterial Chemotherapy is Reliable in Preventing High-Risk Superficial Bladder Cancer from Recurrence and Progression. Journal of Chemotherapy 21:6, pages 681-686.
Read now

Articles from other publishers (2)

Zhongbao Zhou, Yuanshan Cui, Shuangfeng Huang, Zhipeng Chen & Yong Zhang. (2021) The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study. Frontiers in Oncology 11.
Crossref
Fan Lian, Wenchuan Chen, Yiming Liu, Long Shen, Wenzhe Fan, Wei Cui, Yue Zhao, Jiaping Li & Yu Wang. (2019) Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer. Journal of Cancer Research and Clinical Oncology 145:6, pages 1625-1633.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.